CD7 and T-cell leukemia: In essence, multiplexed BE was performed to simultaneously knockout CD7, TRAC and CD52 by introduction of nonsense mutations into these genes to improve the efficacy of off-the-shelf CAR-T cells to target T-cell leukemia by preventing fratricide of CAR-T cells, graft-versus-host disease and resistance to lymphocytic leukemia drugs.